Document is current
Any future updates will be listed below
-
Authors
Sherratt-Mayhew, Sam https://orcid.org/0009-0001-6197-3645
Page, Charles https://orcid.org/0009-0007-6687-9045
Lowe, Michael https://orcid.org/0000-0001-5712-3800
Mollan, Susan P. https://orcid.org/0000-0002-6314-4437
Berman, Gabriele https://orcid.org/0009-0008-3390-9508
- License Information
-
More Information
Article History
Received: 9 July 2025
Revised: 17 July 2025
Accepted: 23 July 2025
First Online: 25 August 2025
Competing interests
: SPM reports consultancy fees (Invex Therapeutics); advisory board fees (Ocular therapeutix); speaker fees (Teva); travel (Abbvie and European Alliance of Associations for Rheumatology); receipt of equipment (Heidelberg Engineering). SPM is a section editor at Eye Journal. The authors declare no other financial relationships with any organisations that might have an interest in the submitted work, and no other relationships or activities that could appear to have influenced the submitted work.
